Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Review, H2 2018

Global Markets Direct’s, ‘Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Review, H2 2018’, provides an overview of the Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)

- The report reviews pipeline therapeutics for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) therapeutics and enlists all their major and minor projects

- The report assesses Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AbbVie Inc

Actinium Pharmaceuticals Inc

ADC Therapeutics SA

Affimed GmbH

AlfaSigma SpA

Alissa Pharma

Amgen Inc

AstraZeneca Plc

Aurigene Discovery Technologies Ltd

BeiGene Ltd

Biohaven ...

AbbVie Inc

Actinium Pharmaceuticals Inc

ADC Therapeutics SA

Affimed GmbH

AlfaSigma SpA

Alissa Pharma

Amgen Inc

AstraZeneca Plc

Aurigene Discovery Technologies Ltd

BeiGene Ltd

Biohaven Pharmaceutical Holding Company Ltd

Bristol-Myers Squibb Co

CBT Pharmaceuticals Inc

Celgene Corp

Cell Medica Ltd

Celldex Therapeutics Inc

Cellectar Biosciences Inc

Cellectis SA

Celleron Therapeutics Ltd

Cellestia Biotech AG

Cellular Biomedicine Group Inc

Checkpoint Therapeutics Inc

Chipscreen Biosciences Ltd

Curis Inc

Eli Lilly and Co

F. Hoffmann-La Roche Ltd

Faron Pharmaceuticals Oy

FLX Bio Inc

Immunomedics Inc

Incyte Corp

Jiangsu Hengrui Medicine Co Ltd

Kiromic Inc

Kite Pharma Inc

MedImmune LLC

Merck KGaA

Millennium Pharmaceuticals Inc

Miltenyi Biotec GmbH

Mirati Therapeutics Inc

Molecular Templates Inc

NantKwest Inc

NBE-Therapeutics AG

Rafael Pharmaceuticals Inc

Regeneron Pharmaceuticals Inc

Rhizen Pharmaceuticals SA

Rich Pharmaceuticals Inc

Seattle Genetics Inc

Selvita SA

Sichuan Kelun Pharmaceutical Co Ltd

Syndax Pharmaceuticals Inc

TaiGen Biotechnology Co Ltd

Taiwan Liposome Company Ltd

TRACON Pharmaceuticals Inc

Trillium Therapeutics Inc

Table of Contents

Table of Contents

Table of Contents 2

Introduction 5

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Overview 6

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Therapeutics Development 7

Hodgkin ...

Table of Contents

Table of Contents 2

Introduction 5

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Overview 6

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Therapeutics Development 7

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Therapeutics Assessment 20

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Companies Involved in Therapeutics Development 32

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Drug Profiles 59

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Dormant Projects 524

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Discontinued Products 528

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Product Development Milestones 529

Appendix 543

List of Tables

List of Tables

Number of Products under Development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), H2 2018

Number of Products under Development by Companies, H2 2018 ...

List of Tables

Number of Products under Development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..2), H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..3), H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Products under Development by Companies, H2 2018 (Contd..2), H2 2018

Products under Development by Companies, H2 2018 (Contd..3), H2 2018

Products under Development by Companies, H2 2018 (Contd..4), H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Target, H2 2018 (Contd..1), H2 2018

Number of Products by Stage and Target, H2 2018 (Contd..2), H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018 (Contd..1), H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018 (Contd..2), H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by AbbVie Inc, H2 2018

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Actinium Pharmaceuticals Inc, H2 2018

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by ADC Therapeutics SA, H2 2018

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Affimed GmbH, H2 2018

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by AlfaSigma SpA, H2 2018

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Alissa Pharma, H2 2018

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Amgen Inc, H2 2018

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by AstraZeneca Plc, H2 2018

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Aurigene Discovery Technologies Ltd, H2 2018

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by BeiGene Ltd, H2 2018

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Biohaven Pharmaceutical Holding Company Ltd, H2 2018

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Bristol-Myers Squibb Co, H2 2018

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by CBT Pharmaceuticals Inc, H2 2018

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Celgene Corp, H2 2018

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Cell Medica Ltd, H2 2018

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Celldex Therapeutics Inc, H2 2018

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Cellectar Biosciences Inc, H2 2018

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Cellectis SA, H2 2018

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Celleron Therapeutics Ltd, H2 2018

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Cellestia Biotech AG, H2 2018

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Cellular Biomedicine Group Inc, H2 2018

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Checkpoint Therapeutics Inc, H2 2018

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Chipscreen Biosciences Ltd, H2 2018

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Curis Inc, H2 2018

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Eli Lilly and Co, H2 2018

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by F. Hoffmann-La Roche Ltd, H2 2018

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Faron Pharmaceuticals Oy, H2 2018

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by FLX Bio Inc, H2 2018

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Immunomedics Inc, H2 2018

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Incyte Corp, H2 2018

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2018

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Kiromic Inc, H2 2018

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Kite Pharma Inc, H2 2018

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by MedImmune LLC, H2 2018

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Merck KGaA, H2 2018

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Millennium Pharmaceuticals Inc, H2 2018

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Miltenyi Biotec GmbH, H2 2018

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Mirati Therapeutics Inc, H2 2018

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Molecular Templates Inc, H2 2018

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by NantKwest Inc, H2 2018

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by NBE-Therapeutics AG, H2 2018

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Rafael Pharmaceuticals Inc, H2 2018

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Regeneron Pharmaceuticals Inc, H2 2018

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Rhizen Pharmaceuticals SA, H2 2018

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Rich Pharmaceuticals Inc, H2 2018

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Seattle Genetics Inc, H2 2018

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Selvita SA, H2 2018

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Sichuan Kelun Pharmaceutical Co Ltd, H2 2018

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Syndax Pharmaceuticals Inc, H2 2018

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by TaiGen Biotechnology Co Ltd, H2 2018

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Taiwan Liposome Company Ltd, H2 2018

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by TRACON Pharmaceuticals Inc, H2 2018

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Trillium Therapeutics Inc, H2 2018

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Dormant Projects, H2 2018

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Dormant Projects, H2 2018 (Contd..1), H2 2018

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Dormant Projects, H2 2018 (Contd..2), H2 2018

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Dormant Projects, H2 2018 (Contd..3), H2 2018

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Discontinued Products, H2 2018

List of Figures

List of Figures

Number of Products under Development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), H2 2018

Number of Products under Development by Companies, H2 2018 ...

List of Figures

Number of Products under Development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports